Amgen Cash Flow Statement
AMGN / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Amgen generated $10.0B in operating cash flow and $8.1B in free cash flow in FY2025. Free cash flow margin was 22.0% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $7.7B | $4.1B | $6.7B | $6.6B | $5.9B | $7.3B | $2.0B | $7.7B | $6.9B | $5.2B | $6.9B | $4.3B | $5.1B | $4.3B | $3.7B |
| Depreciation & Amortization | $5.2B | $5.6B | $4.1B | $3.4B | $3.4B | $3.6B | $2.0B | $2.1B | $2.1B | $2.1B | $2.1B | $1.1B | $1.3B | $1.1B | $1.1B |
| Operating Cash Flow | $10.0B | $11.5B | $8.5B | $9.7B | $9.3B | $10.5B | $11.2B | $10.4B | $9.7B | $9.0B | $9.7B | $5.9B | $6.3B | $5.9B | $5.1B |
| Capital Expenditures | $1.9B | $1.1B | $1.1B | $936.0M | $880.0M | $608.0M | $664.0M | $738.0M | $594.0M | $718.0M | $594.0M | $689.0M | $693.0M | $689.0M | $567.0M |
| Free Cash Flow | $8.1B | $10.4B | $7.4B | $8.8B | $8.4B | $9.9B | $10.5B | $9.6B | $9.1B | $8.2B | $9.1B | $5.2B | $5.6B | $5.2B | $4.6B |
| Share Buybacks | $0 | $200.0M | $0 | $6.4B | $5.0B | $3.5B | $3.2B | $3.0B | $1.9B | $138.0M | $1.9B | $4.6B | $832.0M | $4.6B | $8.3B |
| Dividends Paid | $5.1B | $4.8B | $4.6B | $4.2B | $4.0B | $3.8B | $3.4B | $3.0B | $2.4B | $1.9B | $2.4B | $1.1B | $1.4B | $1.1B | $500.0M |
| FCF Margin | 22.0% | 31.1% | 26.1% | 33.4% | 32.3% | 38.9% | 46.0% | 41.8% | 42.2% | 41.0% | 42.2% | 30.1% | 30.0% | 30.1% | 29.2% |